We are live on
!
Find out more
Squarepoint Portfolio holdings
AUM
$85.1B
1-Year Est. Return
20.93%
This Fund
S&P 500
This Quarter
Est. Return
+5.99%
1 Year Est. Return
+20.93%
3 Year Est. Return
+51.38%
5 Year Est. Return
+34.63%
10 Year Est. Return
+146.23%
AUM
$63.9B
AUM Growth
+$3.43B
(+5.7%)
Cap. Flow
+$105M
Cap. Flow
% of AUM
0.16%
Top 10 Holdings %
Top 10 Hldgs %
21.18%
Holding
4,866
New
886
Increased
1,406
Reduced
1,667
Closed
823
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$3B |
| 2 |
Microsoft
MSFT
|
+$508M |
| 3 |
State Street Real Estate Select Sector SPDR ETF
XLRE
|
+$209M |
| 4 |
iShares MSCI Emerging Markets ETF
EEM
|
+$190M |
| 5 |
Qualcomm
QCOM
|
+$167M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$711M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$184M |
| 3 |
Oracle
ORCL
|
+$168M |
| 4 |
Gilead Sciences
GILD
|
+$140M |
| 5 |
Snowflake
SNOW
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 8.98% |
| 2 | Consumer Discretionary | 6.34% |
| 3 | Financials | 4.35% |
| 4 | Healthcare | 4.2% |
| 5 | Industrials | 3.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FLNA
3426
Filana Therapeutics
FLNA
$43M
| $304K | ﹤0.01% |
+10,333
| New | +$238K |
|
3427
Suzano
SUZ
$10.2B
| $304K | ﹤0.01% |
+30,397
| New | +$297K |
|
3428
Cato Corp
CATO
$65.9M
| $303K | ﹤0.01% |
60,725
+23,101
| +61% | +$114K |
|
3429
PUT
Joby Aviation
JOBY
$6.82B
| $303K | ﹤0.01% |
60,200
-334,400
| -85% | -$1.82M |
|
3430
Compugen
CGEN
$216M
| $302K | ﹤0.01% |
167,018
+81,325
| +95% | +$148K |
|
3431
Kforce
KFRC
$983M
| $302K | ﹤0.01% |
4,917
-367
| -7% | -$23.5K |
|
|
FIRY
3432
Firy Inc
FIRY
$127M
| $302K | ﹤0.01% |
53,650
+42,190
| +368% | +$260K |
|
3433
CALL
Helmerich & Payne
HP
$3.53B
| $301K | ﹤0.01% |
+9,900
| New | +$342K |
|
3434
Silgan Holdings
SLGN
$4.91B
| $301K | ﹤0.01% |
5,733
-39,376
| -87% | -$1.92M |
|
|
LENZ
3435
LENZ Therapeutics
LENZ
$172M
| $300K | ﹤0.01% |
12,654
+2,177
| +21% | +$48.3K |
|
|
LADR
3436
Ladder Capital
LADR
$1.25B
| $300K | ﹤0.01% |
+25,853
| New | +$307K |
|
3437
PUT
Sarepta Therapeutics
SRPT
$1.66B
| $300K | ﹤0.01% |
+2,400
| New | +$332K |
|
3438
Harmony Biosciences
HRMY
$2.04B
| $300K | ﹤0.01% |
7,490
-42,527
| -85% | -$1.49M |
|
3439
Regal Rexnord
RRX
$14.2B
| $300K | ﹤0.01% |
1,806
-13,411
| -88% | -$2.07M |
|
|
KALV
3440
DELISTED
KalVista Pharmaceuticals
KALV
| $298K | ﹤0.01% |
+25,749
| New | +$324K |
|
3441
Inovio Pharmaceuticals
INO
$79.8M
| $298K | ﹤0.01% |
+51,528
| New | +$425K |
|
3442
Varex Imaging
VREX
$460M
| $298K | ﹤0.01% |
24,976
-1,404
| -5% | -$17.9K |
|
|
GOGL
3443
DELISTED
Golden Ocean Group
GOGL
| $297K | ﹤0.01% |
+22,228
| New | +$276K |
|
3444
CALL
Rentokil
RTO
$14.3B
| $297K | ﹤0.01% |
11,900
-78,100
| -87% | -$2.31M |
|
3445
Lexicon Pharmaceuticals
LXRX
$1.02B
| $296K | ﹤0.01% |
+188,842
| New | +$336K |
|
3446
iShares ESG Aware MSCI EM ETF
ESGE
$6.51B
| $296K | ﹤0.01% |
+8,142
| New | +$278K |
|
3447
CGI
GIB
$13.9B
| $296K | ﹤0.01% |
+2,576
| New | +$281K |
|
3448
Pliant Therapeutics
PLRX
$67.5M
| $296K | ﹤0.01% |
26,382
-54,093
| -67% | -$677K |
|
3449
Xenon Pharmaceuticals
XENE
$6.32B
| $295K | ﹤0.01% |
+7,504
| New | +$303K |
|
3450
PC Connection
CNXN
$2.05B
| $295K | ﹤0.01% |
3,908
-1,730
| -31% | -$120K |
|
Similar funds
Squarepoint's Q3 2024 Portfolio in Review
As of Q3 2024, Squarepoint held 4,866 positions worth $63.9B, up 5.7% from $60.5B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Squarepoint's Q3 2024 filing shows 886 new, 1,406 increased, 1,667 reduced and 823 closed positions. Its largest new stake was State Street Real Estate Select Sector SPDR ETF: 4,950,000 shares worth $221M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $711M.
By sector, the portfolio is most concentrated in Technology at 9% of assets, down from 9.1% a quarter earlier, followed by Consumer Discretionary and Financials.
- Squarepoint's largest Q3 2024 buy was State Street Real Estate Select Sector SPDR ETF: 4,950,000 shares worth $221M.
- Squarepoint added most to iShares Core S&P 500 ETF in Q3 2024, an estimated $3B increase.
- Squarepoint's biggest Q3 2024 reduction was Bristol-Myers Squibb, cutting an estimated $184M.
- Squarepoint fully exited State Street SPDR S&P 500 ETF Trust in Q3 2024, selling an estimated $711M.
- Squarepoint's ten largest holdings make up 21% of its $63.9B portfolio in Q3 2024.
- Squarepoint opened 886 new positions and closed 823 in Q3 2024.
- Squarepoint's portfolio value rose 5.7% quarter-over-quarter to $63.9B.
Based on Squarepoint's 13F filing for Q3 2024, filed 14 Nov 2024.